

Q2 2019 Quarterly Review

First Eagle Amundi International Fund







Q2 2019 COMMENTARY FIRST EAGLE AMUNDI INTERNATIONAL FUND

The quarter was defined by a myriad of concerns that pushed and pulled on investor sentiment. Global equity markets continued their positive march during the second quarter after kicking off 2019 with the strongest quarter since 2010. MSCI World ended June just 2.6% below its historically highest peak and registered a 17.0% total return over the first 6 months of the year. However, these seemingly sunny skies did not come without some rain. MSCI World was down 5.8% by June 3rd from its high in early May. The flurry of uncertainties pervading the markets at the start of the quarter surrounding the US-China trade war were finally at bay by the end of June after President Trump and Xi Jinping agreed to restart trade discussions. Also, geopolitical issues spiked during the quarter, particularly in the Middle East, following the attacks on two oil tankers near the strategic Strait of Hormuz. Meanwhile, the quarter also marked a turn to more dovish monetary policy by the Fed and ECB. Global markets responded positively to this shift in protocol, recouping losses during the downswing of the earlier months. Meanwhile, bond yields dropped in both the US and Europe, increasing the global stock of subzero interest rate debt to above 13 trillion USD.

As markets reached new peaks, the Fund captured approximately 82.5% of the upside for the second quarter, registering a 3.3% return versus a 4.0% return for the MCSI World Index. YTD, the Fund was up 13.1% versus 17.0% for the Index, capturing 77.1% of the market rebound with approximately 71% exposure to equities.

From a sector perspective, equity exposure to Financials, Consumer Discretionary, and Industrials contributed the most to positive performance while exposure to Energy, Utilities, and Consumer Staples detracted the most from positive performance.

Regarding the Fund's portfolio evolution throughout the quarter, exposure to cash and cash equivalents was rather stable, ending the second quarter at similar levels where it started, at 15.4%. Increased volatility provided a narrow window of discounted investment opportunities that we participated in, primarily by adding on to existing portfolio holdings.

After fully exiting **Devon Energy**, **NSC Groupe** and **Canadian Natural Resources** in the first quarter, the investment team made a few additional exits in the months following. During the second quarter, the investment team fully exited two longer-term holdings of the Fund, **Secom Joshinetsu** and **Haw Par**. Initially purchased in 2007, Secom Joshinetsu, is a Japan-based company that is part of the larger Secom Group and has two business segments, 1.) related to security systems and 2.) related to medical, electrical and construction endeavors. An even older name in the portfolio, held for over 15 years, is Haw Par, the Singapore-based healthcare, leisure, property and investments company that is most recognized for its Tiger Balm branded liniment product.

Additionally, we exited three US-based businesses when their shares reflected the team's estimate of their intrinsic values including **Xilinx**, designer of programmable devices including integrated circuits and software design tools (e.g. used for auto collision prevention), **Cintas**, provider of business services such as employee uniform rentals, and **Cincinnati Financial**, provider of property and casualty insurance. Similarly, we exited our position in **Gazprom** (ADR), the larger Russian energy company, when share prices reflected its estimated intrinsic value.

In terms of new positions, the investment team initiated one new equity holding during Q2 2019, a South Korean multinational electronics conglomerate.

Gold pricing experienced a strong uptick in June, reaching a six-year high. Mainly due to this strong price appreciation, the Fund's exposure to gold-related securities increased to encompass 13.7% of the portfolio by the end of the quarter and made a strong contribution to positive returns. Goldrelated securities are an integral part of the team's investment process and are incorporated as a potential hedge against uncertain market outcomes. The portfolio weight of gold-related securities is substantially higher than it was at the same time last year. This structural difference in the portfolio reflects a growing risk landscape as we face a more complex, multi-polar, populist and overindebted world.

In this uncertain environment, with fear and complacency as alternate market drivers, we continue to focus on crafting a portfolio structured to endure potentially more challenging times ahead. We do so by owning companies that we believe control scarce, hard to replicate and resilient assets, both intangible and real, that we seek to purchase with a discount in price, providing us with a margin of safety.



MATT MCLENNAN, CFA Portfolio Manager & Head of Global Value Team







MANISH GUPTA Associate Portfolio Manager


Q2 2019 PORTFOLIO SNAPSHOT

FIRST EAGLE AMUNDI INTERNATIONAL FUND (AUC)

Performance Since Inception - Growth of \$100



Asset Breakdown



Largest Contributors to Performance for Q2 2019

Highest (%)	
KDDI	0.22
Danone	0.17
Oracle	0.15
W. R. Berkley Corporation	0.14
Flowserve	0.14

AUM

\$8,507.64 Million

No. of Holdings

143

Returns (%)

Cumulative	
Q2 2019	3.27
YTD	13.12
Annualized	
3 Year	5.39
5 Year	3.04
10 Year	6.83
Since Inception	8.94

Largest Equity Holdings (%)

• • • •	
Oracle	2.44
Comcast	2.00
Exxon Mobil	1.87
FANUC	1.68
Schlumberger	1.59
Weyerhaeuser	1.46
Danone	1.42
KDDI	1.32
British American Tobacco	1.32
Sompo	1.26
Total % of Portfolio	16.36

Lowest (%)

British American Tobacco	-0.24
National Oilwell Varco	-0.18
Teradata	-0.17
Bank of New York Mellon	-0.16
3M	-0.16

Source: Amundi, as of end of June 2019, net performance in USD. Retail share class (AU-C). Share-class inception date August 12, 1996. Current allocation may be changed without prior notice within the limits stated in the Prospectus. Past performance is not a reliable indicator of future returns. The performance are mentioned for indicative purposes only and the value of investments may vary upwards or downwards according to market conditions.

Important Information

This material is provided to Professional Clients, including financial intermediaries, and is not intended for and should not be provided to the public. This document contains information about investment services provided by Amundi group companies or undertakings for collective investment in transferable securities (the "Funds") established under the laws of Luxembourg and authorised for public distribution by the Commission de Surveillance du Secteur Financier. The management company of

- Amundi Funds, Amundi Fund Solutions and First Eagle Amundi is Amundi Luxembourg S.A., 5, allée Scheffer, L-2520 Luxembourg;
- CPR Invest is CPR Asset Management, 90 Boulevard Pasteur, 75015 Paris, France;

• KBI Institutional ICAV is KBI Global Investors Ltd., 2 Harbourmaster Place, International Financial Services Centre, Dublin 1, Ireland. This material is information purposes only, is not a recommendation, financial analysis or advice, and does not constitute a solicitation, invitation or offer to purchase or sell any the Funds or services described herein in any jurisdiction where such offer, solicitation or invitation would be unlawful. This material has not been submitted for regulatory approval and is solely for issue in permitted jurisdictions and to persons who may receive it without breaching applicable legal or regulatory requirements. The information contained in this document is confidential and shall not, without prior written approval

of Amundi Ireland Limited ("Amundi"), be copied, reproduced, modified, or distributed, to any third person or entity in any country. The Funds described in this document may not be available to all investors and may not be registered for public distribution with the relevant authorities in all countries.

Investment involves risk. Past performance is not a guarantee or indication of future results. Investment return and the principal value of an investment in the Funds or other investment product may go up or down and may result in the loss of the amount originally invested. All investors should seek professional advice prior to any investment decision, in order to determine the risks associated with the investment and its suitability. It is the responsibility of investors to read the legal documents in force in particular the current prospectus for each Fund. Subscriptions in the Funds will only be accepted on the basis of their latest prospectus and/or the Key Investor Information Document ("KIID" available in local language in EU countries of registration) which, together with the latest annual and semi-annual reports may be obtained, free of charge, at the registered office of Amundi Luxembourg S.A. or at www.amundi.lu. In Italy, this documentation is available at www.amundi.it. Information relating to costs and charges of the Funds may be obtained from the KIID.

The performance data do not take account of the commissions and costs incurred on the issue and redemption of units of the Funds.

In EEA Member States, the content of this document is approved by Amundi for use with Professional Clients (as defined in EU Directive 2004/39/EC) only and shall not be distributed to the public. Amundi Ireland Limited is authorised and regulated by the Central Bank of Ireland. KBI Institutional ICAV is a collective investment scheme established under Irish Iaw. Société Générale, Dublin Branch 3rd Floor, IFSC House, IFS, Dublin 1 is the facilities agent for those sub-funds of Amundi Funds, First Eagle Amundi registered in Ireland.

In the UK, this document is approved for distribution by Amundi Asset Management (London Branch), 41 Lothbury, London, EC2R 7HF. Amundi Asset Management is a portfolio management company authorised by the Autorité des Marchés Financiers in France and its London Branch is subject to limited regulation by the UK Financial Conduct Authority. Further information of this authorisation is available on request. Amundi Funds SICAV, First Eagle Amundi SICAV, CPR Invest SICAV and KBI Institutional ICAV are recognised schemes for the purposes of Section 264 of the Financial Services and Markets Act 2000 (the "FSMA") of the UK and can be promoted and sold direct to the public in the United Kingdom subject to compliance with the FSMA and applicable regulations made thereunder. This document is addressed only to those persons in the UK falling within one or more of the following exemptions from the restrictions in s 238 FSMA:

• authorised firms under FSMA and certain other investment professionals falling within article 14 of the FSMA (Promotion of Collective Investment Schemes) (Exemptions) Order 2001, as amended (the "CIS Order") and their directors, officers and employees acting for such entities in relation to investment;

• high value entities falling within article 22 CIS Order and their directors, officers and employees acting for such entities in relation to investment;

• other persons who are in accordance with the Rules of the FCA prior to 1 November 2007 classified as Intermediate Customers or Market Counterparties or on or thereafter classified as Professional Clients or Eligible Counterparties.

The distribution of this document to any person in the UK not falling within one of the above categories is not permitted by Amundi Asset Management London Branch and may contravene FSMA. No person in the UK falling outside those categories should rely or act on it for any purposes whatsoever.

In Switzerland, this document is for Qualified Investors (as defined in Swiss Collective Investment Schemes Act of 23 June 2006 as amended or supplemented) use only and shall not be distributed to the public.

The Representative and Paying Agent for Funds registered for distribution in Switzerland are, in respect of Amundi Funds and First Eagle Amundi: Representative - CACEIS (Switzerland) SA and Paying Agent - CACEIS Bank, Nyon Branch both at 35 Route de Signy, Case postale 2259, CH-1260 Nyon; KBI Institutional Fund ICAV: Representative – ACOLIN Fund Services AG, Affolternstrasse 56, CH-8050 Zurich and Paying Agent – NPB Neue Privat Bank AG, Limmatquai 1, CH-8001 Zurich. Free copies of the prospectus, key investor information documents, annual and semi-annual reports, management regulations and other information are available at the representative's address shown above.

Amundi Suisse SA has been authorized in Switzerland to distribute the Funds. Amundi Suisse SA receives from Amundi Luxembourg S.A. or other Amundi group entities, compensation under article 34 al. 2bis of the OPCC (Ordonnance sur les placements collectifs de capitaux). Such compensation may constitute a part of the management fees stated in the prospectus of the Funds and further information may be obtained upon written request to Amundi Suisse S.A., 6-8 rue de Candolle 1205 Genève Suisse.

In France, a free prospectus is available from Amundi Asset Management, 90 boulevard Pasteur -75015 Paris - France - 437 574 452 RCS Paris France or from the centralisateur of the Funds which in the case of Amundi Funds SICAV and CPR Invest SICAV is CACEIS Bank SA, 1-3 place Valhubert, 75013 Paris and in the case of First Eagle Amundi SICAV is Société Générale, 29 Boulevard Haussmann, 75008 Paris.

In Germany, for additional information on the Fund, a free prospectus may be requested from Amundi Deutschland GmbH, Arnulfstr. 124-126 80636 Munich, Germany (Tel. +49.89.99.226.0).

In Austria the paying agents for Funds registered for public distribution in are, in respect of Amundi Fund Solutions: UniCredit Bank Austria AG, Schottengasse 6-8, A-1010 Vienna Amundi Funds: Meinl Bank Aktiengesellschaft, Bauernmarkt 2, A-1010 Vienna; First Eagle Amundi: Société Générale, Vienna Branch, Prinz Eugen Strasse 8 - 10/5/Top 11, A-1040 Vienna; CPR Invest: Raiffeisen Bank International AG, Am Stadtpark 9, A-1030 Wien; and KBI Institutional ICAV: Erste Bank der oesterreichischen Sparkassen AG, Am Belvedere 1, A-1100 Vienna. In Spain, the Funds are foreign undertakings for collective investment registered with the CNMV and numbered Amundi S.F (493); Amundi Fund Solutions (1333); Amundi Funds (61) First Eagle Amundi (111); CPR Invest (1564); and KBI Institutional ICAV (1248). Any investment in the Funds or their respective subfunds must be made through a registered Spanish distributor. Amundi Iberia SGIIC, SAU, is the main distributor of the Funds in Spain, registered with number 31 in the CNMV's SGIIC registry, with address at P^o de la Castellana 1, Madrid 28046. A list of all Spanish distributors may be obtained from the CNMV at www.cnmv.es. Units may only be acquired on the basis of the most recent prospectus, key investor information document and further current documentation, which may be obtained from the CNMV.

In Chile and Peru, this document is approved for use by Administradora de Fondos de Pensiones/Pension Fund Administrators and other institutional investors. In Mexico, this document is approved for use with institutional investors. It may not be distributed to third parties or to the public.

In Singapore, this document is provided solely for the use of distributors and financial advisors only and is not to be distributed to the retail public. Distribution occurs through Amundi Singapore Ltd, 80 Raffles Place, UOB Plaza 1, #23-01, Singapore 048624. This document contains information about certain sub-funds of Amundi Funds and First Eagle Amundi SICAV which may be registered as recognised schemes in Singapore under the Securities and Futures Act (Cap. 289) of Singapore ("SFA"), or notified as restricted schemes under the Sixth Schedule to the Securities and Futures (Offers of Investments) (Collective Investment Schemes) Regulations 2005. For the sub-funds or relevant share/unit classes notified as restricted schemes in Singapore, such sub-funds or relevant share/unit classes are not authorised or recognised by the Monetary Authority of Singapore ("MAS") and are not allowed to be offered to the Singapore real public. Accordingly, this document and the material contained within, may not be circulated or distributed, nor may the relevant share/units be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 304 of the SFA, (ii) to a relevant person pursuant to Section 305(1), or any person pursuant to Section 305(2), and in accordance with the conditions specified in Section 305 of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. In other Asian jurisdictions, for use by licensed intermediaries only and not to be distributed to the public.

This information is not for distribution and does not constitute an offer to sell or the solicitation of any offer to buy any securities or services in the United States or in any of its territories or possessions subject to its jurisdiction to or for the benefit of any U.S. Person (as defined in the prospectus of the Funds). The Funds have not been registered in the United States under the Investment Company Act of 1940 and units of the Funds are not registered in the United States under the Securities Act of 1933.

This document is not intended for and no reliance can be placed on this document by persons falling outside of these categories in the above mentioned jurisdictions.

In jurisdictions other than those specified above, this document is for the sole use of the professional clients and intermediaries to whom it is addressed. It is not to be distributed to the public or to other third parties and the use of the information provided by anyone other than the addressee is not authorised. This material, is based on sources that Amundi considers to be reliable at the time of publication. Data, opinions and analysis may be changed without notice. Amundi accepts no liability whatsoever, whether direct or indirect, that may arise from the use of information contained in this material. Amundi can in no way be held responsible for any decision or investment made on the basis of information contained in this material.

© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar; (2) may not be copied or redistributed; (3) do not constitute investment advice; (4) are provided solely for informational purposes; (5) are not warranted to be complete, accurate or timely; and (6) may be drawn from fund data published on various dates. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don't make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The Funds or securities referred to herein are not sponsored, endorsed, or promoted by MSCI, and MSCI bears no liability with respect to any such Funds or securities or any index on which such Funds or securities are based. The offering documents of the Funds contain a more detailed description of the limited relationship MSCI has with Amundi and any relevant Funds.

Date of First Use: 11 July 2019.

Doc ID: 894648

www.amundi.com

